National Compounding Pharmacy OptioRx Files for Bankruptcy


Specialty Pharmacy chain OptioRx, based in Northbrook, Ill., has filed for Chapter 11 bankruptcy protection. Founded in 2018, OptioRx operates specialty pharmacy segments across 18 locations in seven states, employing 260 workers, but has faced financial challenges due to discontinued products, a failed compounding strategy and competing pharmacies, according to TheStreet, June 11, 2024.

OptioRx is a national compounding pharmacy that focuses on providing best-in-class patient care. OptioRx’s pharmacies provide medications to meet the unique needs of each patient, including wellness, hormone compounding, fertility medications, veterinary and animal-free compounding.

OptioRx also offers hospice pharmacy services that focuses on the quality of life for people who are experiencing an advanced, life-limiting illness.

OptioRx’s specialty care pharmacies specialize in dispensing hard to find medications for a variety of specialties, including Dermatology, Neurology, Podiatry, Ophthalmology, and Women’s Health.

OptioRx, through its innovative care model and 18 locations, services patients nationally, giving patients the option of receiving prescriptions and patient care face-to-face or at-home delivery.

OptioRx has designed The HUB to offer a consistent patient experience. All prescriptions arrive in The HUB, the central processing center. The same group of technicians processes all orders; they get to know patients and their needs.

OptioRx operates 18 locations in seven states, including: California, Texas, Wisconsin, Illinois, Ohio, New York, and Florida.

In July 2018, Capitala Group, a provider of capital to lower and traditional middle market companies, originated a combination of a senior secured debt facility and minority equity totaling $27.3 million to support Cold Bore Capital in the

In November 2020, Capitala Group successfully exited its senior secured debt and minority equity investment in OptioRx.